Fosun Pharmaceutical: the subsidiary plans to invest 10 million yuan to participate in the establishment of the target fund
Financial Associated Press, Dec. 28 - Fosun Pharmaceutical announced that Ningbo Fuying, the company's holding subsidiary, and Sinopharm CICC plan to jointly contribute to the establishment of a target fund, which is specially used for the investment in Chenxi health. The target fund plans to raise 11.11 million yuan, of which Ningbo Fuying (as LP) and Sinopharm Zhongjin (as GP) plan to contribute 10 million yuan and 1.11 million yuan in cash to subscribe for the equivalent property shares of the target fund.
This text is a result of machine translation.
Related companies：
Briefing Jun 25, 2022 06:50 AM
In the half year, the 36billion yuan production expansion plan has been thrown away, and the competition in the stock market of Baijiu is fierce
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 06, 2023 08:30 AM
Jan 05, 2023 07:33 PM
Briefing Jun 24, 2022 10:29 AM
· Consumer Staples
Dongbei group: the holding foundry subsidiary currently produces brake discs and other products at full capacity, with orders in short supply
Healthcare, Financials
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Tianci materials: it is planned to buy back the company's shares of RMB 250million to RMB 500million
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
Apr 23, 2024 02:21 PM